Skip to main content
Premium Trial:

Request an Annual Quote

New Product Watch: Oct 25, 2011

Premium

Microarrays Inc. this week launched three MI PathArray assays for studying targeted biological pathways. The new arrays cover pathways associated with apoptosis, growth factors, and inflammation. Each slide contains four subarrays with an average coverage of three probes per gene plus controls and probes for data normalization. On its website, MI says it plans to introduce arrays for studying cancer and transcription factors in the future. The company also plans to eventually sell kits and hardware for sample preparation, processing, and array hybridization.

BioArray News spoke with CEO Joel Peek about the new offering earlier this month (BAN 10/11/11).

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.